CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$2.39
0.02 (0.84%)
▲
5d:
-4.02%
30d:
-5.53%
90d:
+48.45%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CDXS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CDXS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $2.39, which is considered oversold relative to its 30-day fair value range of $2.44 to $2.68. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.4) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is currently testing key support at $2.32. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CDXS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.58 (+177.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is currently testing key support at $2.32. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CDXS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.58 (+177.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.44 -
$2.68
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 177.8% below Wall St target ($6.58)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.44 -
$2.68
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.32
Resistance Level
$2.69
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.41
Wall Street Target
$6.58
(+177.8%)
Revenue Growth (YoY)
102.1%
Profit Margin
-41.0%
PE vs Historical
-6.4 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 4:52 PM ET
Data refreshes hourly during market hours. Next update: 5:52 PM
Data refreshes hourly during market hours. Next update: 5:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Stefan Lutz
SELL
5862 shares
2026-02-24
Alison Moore
SELL
3826 shares
2026-02-06
Georgia Erbez
SELL
3826 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
